ISIDOR C. BRILL, M.D., F.A.C.P.; PAUL R. BURGNER, M.D.; NORMAN A. DAVID, M.D.
Acetyl-digitoxin2 is the most recently introduced cardiac glycoside undergoing clinical scrutiny. Chemically, it is unique in being the first pure crystalline glycoside produced by controlled enzymatic degradation of lanatoside A to remove only the single glucose molecule and leave intact the aglycone-3 digitoxoses-acetyl moiety.1 Experimentally, Rothlin et al.2 and Rothlin and Bircher3 demonstrated that acetyl-digitoxin is well absorbed from the intestinal tract, reduces the heart rate greatly and is less toxic than digitoxin.
Clinically, it was reported by the European workers Loeffler, Essellier and Forster,4 Trolliet et al.,5 Hausler and Hortnagl6 and Heinrich and Delius7 that this new glycoside is
BRILL IC, BURGNER PR, DAVID NA. ACETYL-DIGITOXIN (ACYLANID): RAPID DIGITALIZATION AND MAINTENANCE BY ORAL ADMINISTRATION1. Ann Intern Med. ;44:707–716. doi: 10.7326/0003-4819-44-4-707
Download citation file:
Published: Ann Intern Med. 1956;44(4):707-716.
Cardiology, Education and Training, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use